The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Reletrans 15 micrograms/hour Transdermal Patches

Rowex LtdPA0711/236/003

Main Information

Trade NameReletrans 15 micrograms/hour Transdermal Patches
Active SubstancesBuprenorphine
Dosage FormTransdermal patch
Licence HolderRowex Ltd
Licence NumberPA0711/236/003

Group Information

ATC CodeN02AE Oripavine derivatives
N02AE01 buprenorphine


License statusAuthorised
Licence Issued05/02/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back